Patents by Inventor Valerio TAZZARI

Valerio TAZZARI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of mGlu5 receptors
    Patent number: 11591337
    Abstract: Disclosed are triazole, imidazole and pyrrole condensed piperazine derivatives and their use as allosteric modulators of mGlus receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related either directly or indirectly to glutamate dysfunction, i.e., disorders treatable by positive allosteric modulation (PAM) or by negative allosteric modulation (NAM) of mGluR5.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: February 28, 2023
    Assignee: Recordati Industria Chimica e Farmaceutica S.p.A.
    Inventors: Davide Graziani, Carlo Riva, Sergio Menegon, Valerio Tazzari
  • TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS
    Publication number: 20210047331
    Abstract: Disclosed are triazole, imidazole and pyrrole condensed piperazine derivatives and their use as allosteric modulators of mGlus receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related either directly or indirectly to glutamate dysfunction, i.e., disorders treatable by positive allosteric modulation (PAM) or by negative allosteric modulation (NAM) of mGluR5.
    Type: Application
    Filed: January 17, 2019
    Publication date: February 18, 2021
    Inventors: Davide GRAZIANI, Carlo RIVA, Sergio MENEGON, Valerio TAZZARI